Literature DB >> 9197532

Two transcription factors, E1AF and N-myc, correlate with the invasiveness of neuroblastoma cell lines.

K Taguchi1, K Yoshida, F Sasaki, K Fujinaga.   

Abstract

The ets transcription factor E1AF can activate several matrix-degrading metalloproteinase (MMP) genes and is implicated in enhancement of tumor cell invasion. Here we compared the invasive activity of five human neuroblastoma cell lines (TGW, GOTO, SK-N-BE, SK-N-SH and SK-N-AS), which exhibit distinct levels of N-myc amplification, together with the expression of E1AF. Extracellular matrix-degrading proteases and their inhibitor proteins, which play an important role in local invasion, were also analyzed. The activity to invade through reconstituted basement membrane was high in cells (TGW, GOTO, and SK-N-BE) with N-myc amplification, and these cells produced relatively large amounts of E1AF mRNA, correlating with the invasive activities. Of several matrix metalloproteinases (MMPs) and a tissue inhibitor of MMPs (TIMP), only membrane-bound type 1 MMP (MT1-MMP) was specifically detected in N-myc-amplified cells, suggesting a role of MT1-MMP in neuroblastoma cell invasion. MMP-2 (72 kD type IV collagenase), TIMP-1 and TIMP-2 were expressed in all five cell lines. Urokinase-type plasminogen activator was undetectable. These findings indicate that the transcription factors E1AF and N-myc are related to malignant phenotypes of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197532      PMCID: PMC5921427          DOI: 10.1111/j.1349-7006.1997.tb00395.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  48 in total

1.  Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.

Authors:  P H Quax; R T van Leeuwen; H W Verspaget; J H Verheijen
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

2.  Human skin fibroblast collagenase: interaction with substrate and inhibitor.

Authors:  H G Welgus; J J Jeffrey; A Z Eisen; W T Roswit; G P Stricklin
Journal:  Coll Relat Res       Date:  1985-03

Review 3.  Proteinases and extracellular matrix remodeling.

Authors:  C M Alexander; Z Werb
Journal:  Curr Opin Cell Biol       Date:  1989-10       Impact factor: 8.382

4.  Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.

Authors:  D Boyd; G Florent; P Kim; M Brattain
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

5.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2.

Authors:  G I Goldberg; B L Marmer; G A Grant; A Z Eisen; S Wilhelm; C S He
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

6.  Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells.

Authors:  E J Bernhard; S B Gruber; R J Muschel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc.

Authors:  M Schwab; H E Varmus; J M Bishop; K H Grzeschik; S L Naylor; A Y Sakaguchi; G Brodeur; J Trent
Journal:  Nature       Date:  1984 Mar 15-21       Impact factor: 49.962

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.

Authors:  H Sato; M Seiki
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

10.  The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites.

Authors:  A Gutman; B Wasylyk
Journal:  EMBO J       Date:  1990-07       Impact factor: 11.598

View more
  2 in total

1.  Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.

Authors:  Emily Saintas; Liam Abrahams; Gulshan T Ahmad; Anu-Oluwa M Ajakaiye; Abdulaziz S H A M AlHumaidi; Candice Ashmore-Harris; Iain Clark; Usha K Dura; Carine N Fixmer; Chinedu Ike-Morris; Mireia Mato Prado; Danielle Mccullough; Shishir Mishra; Katia M U Schöler; Husne Timur; Maxwell D C Williamson; Markella Alatsatianos; Basma Bahsoun; Edith Blackburn; Catherine E Hogwood; Pamela E Lithgow; Michelle Rowe; Lyto Yiangou; Florian Rothweiler; Jindrich Cinatl; Richard Zehner; Anthony J Baines; Michelle D Garrett; Campbell W Gourlay; Darren K Griffin; William J Gullick; Emma Hargreaves; Mark J Howard; Daniel R Lloyd; Jeremy S Rossman; C Mark Smales; Anastasios D Tsaousis; Tobias von der Haar; Mark N Wass; Martin Michaelis
Journal:  PLoS One       Date:  2017-02-13       Impact factor: 3.240

2.  Requirement of PEA3 for transcriptional activation of FAK gene in tumor metastasis.

Authors:  Shufeng Li; Xiaofeng Huang; Dapeng Zhang; Qilai Huang; Guoshun Pei; Lixiang Wang; Wenhui Jiang; Qingang Hu; Renxiang Tan; Zi-Chun Hua
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.